2013, Rifaximin plus Lactulose in Treatment of Hepatic Encephalopathy, The American Journal of Gastroenterology
Category: Gastroenterology - page 2
A Placebo-controlled Trial of Bezafibrate in Primary Biliary Cholangitis Trial Summarized by: Hajra Munawar, MBBS Hasan Shafiq, MD Contribution to literature This trial revealed that the use of the Bezafibrate (PPAR-a agonist )add-on therapy with ursodeoxycholic acid (UDCA) in patients with primary biliary cholangitis, normalizes the serum levels of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase,..
Summarized by / Author: Rohini Manaktala MD (1), Rooma Nankani MD (1) Summary Reviewer: Paul Robert Anthony Jr. MD (2) Contribution To Literature: This trial revealed the beneficial outcome of treating early gastric cancer with H.pylori eradication therapy and the reduction in future development of metachronous gastric cancer compared to placebo. Description: The goal of the trial..
The use of steroids vs Pentoxifylline in severe alcoholic hepatitis has long been debated. The STOPAH trial published in NEJM in 2015 was a strong 2×2 factorial design, randomized trial that established that neither pentoxifylline nor prednisolone provided significant survival benefit in patients with severe alcoholic hepatitis. Take a look at my visual abstract for..
Contribution by Leon Averbukh, Internal Medicine UConn Health Source: JAMA Neurology